Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
- Authors
- Lee, SH[Lee, S. -H.]; Lee, JK[Lee, J. -K.]; Ahn, MJ[Ahn, M. -J.]; Kim, DW[Kim, D. -W.]; Sun, JM[Sun, J. -M.]; Keam, B[Keam, B.]; Kim, TM[Kim, T. M.]; Heo, DS[Heo, D. S.]; Ahn, JS[Ahn, J. S.]; Choi, YL[Choi, Y. -L.]; Min, HS[Min, H. -S.]; Jeon, YK[Jeon, Y. K.]; Park, K[Park, K.]
- Issue Date
- Feb-2017
- Publisher
- OXFORD UNIV PRESS
- Keywords
- vandetanib; RET rearrangement; non-small cell lung cancer
- Citation
- ANNALS OF ONCOLOGY, v.28, no.2, pp.292 - 297
- Indexed
- SCIE
SCOPUS
- Journal Title
- ANNALS OF ONCOLOGY
- Volume
- 28
- Number
- 2
- Start Page
- 292
- End Page
- 297
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/30344
- DOI
- 10.1093/annonc/mdw559
- ISSN
- 0923-7534
- Abstract
- Background: Chromosomal rearrangements involving RET, which are found in about 1% of non-small cell lung cancer (NSCLC), define a unique molecular subset. We performed this study to examine the efficacy and safety of vandetanib 300 mg daily in this patient population. Patients and methods: This study was a multi-center, open-label, phase II clinical trial. Patients were enrolled if they had metastatic or recurrent NSCLC with a RET rearrangement, which was confirmed by fluorescence in situ hybridization, had progressive disease against platinum-based doublet chemotherapy, and had a performance status of 0-2. The primary endpoint was the objective response rate. Results: A total of 18 patients were enrolled in this study between July 2013 and October 2015. Patients were aged 35-71 years; three had a performance status of 2, and the majority were a heavily pretreated population (two different previous chemotherapy regimens in 72% of the patients). Among the 17 evaluable patients, three had a partial response (objective response rate >= 18%) and eight had a stable disease (disease control rate = 65%). Among these patients, the partial response or disease stabilization was durable for more than 6 months in eight patients. Vandetanib also showed a progression-free survival of 4.5 months, and an overall survival of 11.6 months during a median follow-up duration of 14 months. The safety profile was comparable with previous studies of vandetanib. Most vandetanib-related adverse events were mild with prevalent hypertension and rash (in>70% of patients). Grade 3 toxicity included hypertension (n = 3), QT prolongation (2), and elevation of aminotransferases (1), and as a consequence the dose was reduced in four patients. There were no adverse events associated with grade 4 or 5 toxicity. Conclusion: Vandetanib is moderately active in pretreated patients with advanced NSCLC-harboring RET rearrangements.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.